Furthermore, BTK inhibition reduces CXCR4-mediated signaling and adhesion, releasing CLL cells into the circulation and preventing them from re-entering the CLL protective niche in vivo (74). The gene discussed is CXCR4; the disease is B-cell chronic lymphocytic leukemia.